Press Release: MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland…
Press Release: MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology - Newscast
Wed, 06 Dec 2023 16:00:00 GMT Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039. The allowed claims cover a combination of MN-166 (ibudilast) and ...
Wed, 22 Nov 2023 02:10:00 GMT New data/industry report - Announce new data or an industry report with a press release to strengthen credibility and build authority. New hires/promotions - Highlight the value this person will ...
Sat, 18 Nov 2023 16:00:00 GMT The presentation also included data ... MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release ...
Fri, 17 Nov 2023 04:00:00 GMT Subsets of the data will also be presented today in two ... Cautionary Note Regarding Forward-Looking StatementsThis press release contains “forward-looking” statements within the meaning ...
Thu, 16 Nov 2023 23:00:00 GMT Subsets of the data will also be presented today in two ... www.dayonebio.com or find the Company on LinkedIn or Twitter. This press release contains “forward-looking” statements within ...
